Europe (WHO region) vs Saint Vincent and the Grenadines: Previously treated cases tested for RR-/MDR-TB
Europe (WHO region)
90.0%
in 2024
Saint Vincent and the Grenadines
100.0%
in 2022
Europe (WHO region) rank
2nd
Saint Vincent and the Grenadines rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Europe (WHO region)
- Saint Vincent and the Grenadines
How they compare
Saint Vincent and the Grenadines currently reports 100.0% against 90.0% in Europe (WHO region), a difference of 10.0%.
That makes Saint Vincent and the Grenadines's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 3 times across 5 shared years of data; in 2012 it was Europe (WHO region) ahead.
Europe (WHO region) ranks 2nd and Saint Vincent and the Grenadines ranks 1st of 11 groups.
Europe (WHO region) has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Europe (WHO region) | Saint Vincent and the Grenadines | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 53.3% | 33.3% | 20.0% | Europe (WHO region) |
| 2020s | 94.5% | 50.0% | 44.5% | Europe (WHO region) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Europe (WHO region) or Saint Vincent and the Grenadines?
- Saint Vincent and the Grenadines, at 100.0% against 90.0% in Europe (WHO region) as of 2022.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Europe (WHO region) and Saint Vincent and the Grenadines?
- 10.0%, with Saint Vincent and the Grenadines ahead.
- How many years of comparable data are there for Europe (WHO region) and Saint Vincent and the Grenadines?
- 5 years are reported by both, from 2012 to 2022.
- How do Europe (WHO region) and Saint Vincent and the Grenadines rank globally for previously treated cases tested for rr-/mdr-tb?
- Europe (WHO region) ranks 2nd and Saint Vincent and the Grenadines ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.